- 1 Perceived barriers and facilitators to implementing preventive
- 2 therapy for tuberculosis in Malaysian prisons: Perspectives from
- 3 prison personnel
- 4 Phoebe Chen¹, Frederick Altice^{2,3}, Divya Ghoshal⁴, Ahsan Ahmad^{2,3}, Jiang Long^{1,5},
- 5 Rumana Saifi³, Hui Moon Koh⁶, Naga Nagadevi³, Mohd Norbayusri Baharudin⁷, Esther
- 6 Wong Min Fui⁸, Adeeba Kamarulzaman^{2,3}, Sheela Shenoi^{2,3*}
- 7 ¹ Yale School of Medicine, New Haven, Connecticut, United States of America
- 8 ² Yale School of Medicine AIDS Program, Section of Infectious Diseases, Yale
- 9 University, New Haven, Connecticut, United States of America
- ³ CERIA Center of Excellence for Research in AIDS (CERIA), Universiti Malaya, Kuala
- 11 Lampur, Malaysia
- 12 ⁴ Kansas City University College of Osteopathic Medicine, Kansas City, Missouri,
- 13 United States of America
- ⁵ Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine,
 Shanghai, China
- ⁶ Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lampur,
 Malaysia
- 18 ⁷ Department of Social Administration and Justice, Faculty of Arts and Social Science,
- 19 Universiti Malaya, Kuala Lumpur
- 20 ⁸ Ministry of Health, Malaysia
- 21
- 22 Corresponding Author: sheela.shenoi@yale.edu
- 23 Short title (70 characters): Barriers and facilitators to initiating TPT in Malaysian
- 24 Prisons
- 25 Disclosures:

- 26 SS's spouse worked for Merck pharmaceuticals 1997-2007 and retains company stock
- 27 in his retirement account. There is no conflict of interest, but it is included in the interest
- 28 of full disclosure.
- 29 Keywords:
- 30 Tuberculosis; prevention; prison; health care workers; nominal group technique
- 31
- 32

33 Abstract

Tuberculosis (TB) is a major health threat worldwide. TB is concentrated in prisons,
where TB preventive therapy (TPT) implementation has been limited. Prisons generally,
and especially in Malaysia, are overcrowded, minimally resourced, and have high
prevalence of latent TB.

38 As prison personnel are largely responsible for TPT implementation, their perspectives

39 were sought to identify barriers and potential solutions for implementing TPT in

40 Malaysia's largest prison. A focus group using nominal group technique (NGT) was

41 conducted with 9 prison officers with experience related to TPT to generate a list and

42 rank-order the top TPT barriers. The process was repeated to assess facilitators.

43 The top three barriers to implementing TPT were: 1) disruptions involved in prison

44 activities (e.g., intra- and extra-prison transfers; 8 votes); 2) insufficient workforce (5

45 votes), and unanticipated inter-prison transfers (4 votes). Potential solutions included

46 implementing care coordination protocols between officers and medical staff (8 votes),

47 placing a medical hold until TPT completion (5 votes), and improving medication

48 delivery logistics (4 votes). All prison officers supported a short-course TPT regimen

49 administered once-weekly for 12 weeks (i.e. rifapentine and isoniazid (3HP)), over a

50 daily TPT regimen for 6 months (i.e. isoniazid (26H)), due to less logistics and staff time

51 required.

52 From the perspective of prison officer stakeholders, logistical constraints commonly 53 observed in prisons were perceived to impact the implementation of TPT, yet they 54 prioritized pragmatic solutions that align with known implementation strategies to 55 employ to optimize TPT delivery, including developing stakeholder relationships

between medical and prison personnel and changing infrastructure to address frequent
transfers within and between prisons and the community.

58

59 Introduction:

60 Tuberculosis (TB) is the world's second deadliest infectious disease, second only to 61 COVID-19, despite the existence of highly effective treatment and preventive therapies 62 [1]. A guarter of the global population is estimated to have latent TB infection (LTBI) and 63 are at risk of developing active TB disease [2]. TB disproportionately impacts 64 incarcerated populations, who have a disease burden ten times higher than the general 65 population [3], due to factors like overcrowding, malnutrition, and delayed diagnosis [4]. 66 In Malaysia, over a quarter of the population has LTBI [5], with significantly higher 67 prevalence in Malaysian prisons (68% to 88%), as identified previously [6-8]. TB 68 prevalence is concentrated in prisons and complicated by overcrowding, punitive drug 69 policies, and limited prison resources [4,9]. Structural challenges to TB control in 70 prisons include vulnerable and marginalized populations pre-disposed to high TB risk, 71 inadequate ventilation, poor nutrition, comorbid substance use, and poor access to 72 medical care [10]. Periods of incarceration thus present an opportunity to intervene in 73 the TB epidemic by targeting vulnerable individuals during a critical time period of 74 heightened risk [11]. Even though controlling communicable diseases, including TB, 75 among incarcerated persons is included in Malaysian prison regulations [12], prison 76 management faces difficulties in controlling the disease in the high risk prison 77 environment, hence impacting institutions and creating pressures on treatment quality, 78 incident risk, and health of both staff and incarcerated persons [13].

79 TB preventive therapy (TPT) is a safe, highly efficacious, and cost-effective method to 80 prevent the progression of latent TB infection (LTBI) to active TB disease [2]. TPT is one of the key pillars of WHO's End TB Strategy to control the worldwide TB epidemic 81 82 [2]. In 2018, at the UN High-Level Meeting on TB, all country leaders pledged to provide 83 TPT to at least 30 million people at risk of progression to TB disease by 2022; however, 84 only 15.5 million people received TPT between 2018 and 2022 [3]. Despite advances in 85 shorter and better tolerated TPT regimens and reduced costs, TPT remains underutilized globally [14]. The WHO considers the scale-up of TPT to be critical to the 86 87 End TB Strategy, and UN leaders recently pledged to provide TPT to 45 million people 88 by 2027 [15]. Challenges to scaling up TPT include poor program performance in 89 identifying opportunities to test and treat target populations, limited uptake of shorter 90 TPT regimens, and cost [15,16]. TPT remains unavailable in most prisons, despite a 91 strong case for implementation in this high risk and high prevalence setting. As of 2023, 92 the TB burden in prisons is substantial and growing globally [14]. Prisons serve as 93 important reservoirs for TB, including multi-drug-resistant (MDR) TB, which is 94 transmitted to the general population through the prison workforce and release of 95 incarcerated persons [11,17–19].

To scale up TPT in prisons, a better understanding of the implementation context is required. To date, there is limited research informing TPT implementation in low- and middle-income countries (LMICs), particularly within prisons [17,20–24]. It is difficult to implement TPT in the prison environment without relevant stakeholder input on context and facilitators. Therefore, it is crucial to obtain insights from prison staff who would administer and coordinate TPT initiatives. This study elicited prison officers'

102 perspectives on TPT barriers and facilitators in Malaysia's largest prison, which was

103 vital to filling in the evidence gap using an established implementation framework.

104 Methods

105 To understand the barriers to implementing TPT in prisons in Malaysia, we used the 106 established Practical Robust Implementation and Sustainability Model (PRISM), which 107 expands the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) 108 framework to identify contextual factors to guide our pre-implementation process. Since 109 multiple factors may influence TPT implementation, we examined the inner context by 110 interviewing prison officers who are key implementers and can either impede or 111 promote TPT adoption and implementation. In Malaysia, the prevalence of latent TB 112 among prison officers is approximately 81%, as high as it is for people in prison, making 113 prisons a high-risk environment to anyone in this setting [25]. As such, they are key

114 stakeholders for whether and how TPT is implemented.

115 Participants and Setting

116 In July 2023, we recruited 10 participants from Malaysia's largest prison near Kuala 117 Lumpur using purposive sampling. The prison director introduced the study and invited 118 10 prison officers to participate. Eligibility included employment at the prison for at least 119 6 months and had direct experience interfacing with medical staff and assisting with 120 medication administration. Prison officers had no formal TB or TPT training, though they 121 possessed a basic understanding of TB informally passed on from prison medical staff. 122 The study was voluntary and conducted in a private room outside the prison with one 123 facilitator and one translator for English and Bahasa Malaysia. One participant

generated ideas but had to leave before voting, leaving 9 participants who contributeddata to the rank-ordering.

126 Kajang Prison houses over 5000 incarcerated persons [26] and is overcrowded, making 127 incarcerated persons vulnerable to TB infection. The medical unit employes 4 128 physicians and 6 medical assistants, with a doctor to patient ratio of 1:1250. All persons 129 newly-admitted to prison undergo screening for HIV; while national guidelines also 130 recommend screening for TB, implementation lags [27]. If a person has symptoms 131 observed by a prison officer or healthcare provider, they are isolated, evaluated, and, if 132 testing positive for active TB, initiated on treatment at a nearby government hospital, 133 with the remainder of treatment to be completed in the prison. There is no standardized 134 protocol for medication administration across prisons. In Kajang prison, the prison 135 officer collects medication from the medical clinic and is responsible for administering

137 **Procedures**

136

138 Participants completed a brief survey prior to the session and provided verbal consent

daily observed therapy in the TB housing unit. TPT is not currently deployed.

and were reminded that the discussion was confidential. No compensation was

140 provided. The study protocol was approved by the Institutional Review Boards at Yale

141 University (#2000020053) and the Universiti Malaya (#17-19-33974), and the Medical

142 Research & Ethics Committee (MREC) at the Malaysian Ministry of Health (#NMRR ID-

143 17-19-33974), with approval from the Malaysian Prison's Department.

144 The focus group was conducted using nominal group technique (NGT). The expert

145 facilitator interacted with participants while research assistants took notes and recorded

responses on a whiteboard for all participants to observe. The session was audio-recorded, transcribed, and translated.

148 NGT is a well-established mixed-methods strategy increasingly used in implementation 149 research to rapidly identify barriers and solutions for health service delivery [27–31]. We 150 chose NGT to obtain both quantitative estimates of priority (rank-ordering) and in-depth 151 qualitative information that could be rapidly implemented. Compared to traditional focus 152 groups, NGT also ensures more equitable participation from all participants. The NGT 153 process was as follows: (a) silent generation of ideas in response to the initial question 154 "What gets in the way of prisoners receiving medications to prevent TB every day for 6 155 months?"; (b) round-robin feedback from participants where each participant contributed 156 a single idea on a whiteboard until saturation was reached; (c) clarification of ideas as 157 needed by the moderator, allowing for structured group discussion and evaluation of 158 ideas; some ideas were grouped together by consensus and duplicate items were 159 removed; and (d) individual voting, with each participant allocating up to 3 votes to 160 idea(s) they deemed most important. Votes were tallied and the group decision was 161 mathematically derived through rank-ordering [27]. The facilitator led a final discussion 162 to review the participants' results and ensure that they had face validity among 163 participants. This process was repeated with the second question "What could you do or 164 what would be needed to fix these problems that get in the way?" to elicit proposed 165 solutions based on the top-3 ranked barriers. Last, the facilitator proposed a new idea to 166 "Change to a weekly (not daily medication) for TPT" and asked participants with this 167 new information, how many of their 3 votes, if any, they would re-allocate to this idea.

- 168 Focus group questions were based on prior literature and experts in TB treatment, NGT
- 169 methodology, and prison health.
- 170 Results:

171 **Demographics**

- 172 All participants (n=10) were male prison officers whose mean age was 32.7 years and
- 173 had worked as a prison officer for a mean of 8.6 years. Nine respondents (90%) voted
- 174 on both questions. 1 participant contributed to the discussion but left prior to the first
- 175 round of voting due to urgent prison duties.

176 Perceived Barriers

- **Table 1** presents perceived barriers to implementing TPT in the Malaysian prison
- 178 setting. The top three barriers to TPT delivery were interruptions to the routine prison
- schedule (8 votes), including transfers within the prison and to outside appointments
- 180 (e.g. due to court cases, hospital visits, transfers within prison housing units), limited
- 181 prison staff to ensure TPT delivery (5 votes), and unanticipated transfer to another
- 182 prison (4 votes). The remaining barriers are listed in Table 1.

183 Table 1: Key barriers for implementing TPT in prison (N=9)

Votes	Perceived Barriers
8	Interruptions in prison schedule (e.g. court cases, hospital)
5	Staff too busy – limited workforce
4	Patient is transferred to another prison
3	Released from prison (home, early, parole)
	Transfer to another prison housing unit (officers don't know where the patient
2	is)
2	Medical clinic does not provide meds on time
1	Security concerns (less access in high security)
1	Can't find the patient - locate

- 1 Patient has a side effect
- 0 Prisoner does not inform officer with transfer
- 0 Patient dies
- 0 Patient refuses to take it

184

185 **Perceived Facilitators**

- 186 Table 2 presents perceived facilitators for the 3 main barriers identified. The top three
- 187 solutions were improving care coordination between prison officers and medical staff to
- 188 ensure continued medication delivery when schedule disruptions occurred (8 votes),
- 189 deploying a medical hold to avoid transferring the patient until TPT was competed (5
- 190 votes), and moving medications closer to patient housing units with a supply of
- 191 medication at each prison housing unit (4 votes). The remaining facilitators are listed in
- 192 Table 2.

193 Table 2: Key perceived facilitators for initiating TPT in prison

- Votes Perceived Facilitators
- 8 Coordinate b/t officers and medical staff before transfer, release, or court case
- 5 Use a medical hold until treatment completed
- 4 Move the storage of medications to housing unit
- 3 Officer must check to see if prisoner is on medication before they are released
- 3 Education for officers re: TB adherence
- 3 Segregate patients in special treatment unit near medical clinic
- 1 Train a current officer to be in charge on all TB medications

- 195 Finally, when presented with an option at the end of the NGT session to "Change to a
- 196 weekly (not daily medication)", participants re-allocated 19 votes of 27 votes to this
- 197 option. The majority of participants expressed this change would dramatically improve
- adherence and maximize use of their limited human resources.

199 Discussion

As Malaysia struggles to control its TB epidemic in a country with high TB burden, it is crucial to target TPT to those most vulnerable and accessible – to people in prison where TB prevalence is extraordinarily high (68% to 88%) [6–8]. There have been recent calls for accelerated strategies to screen for TB [10] and to introduce TPT in prisons [14], yet guidelines on how to best deliver TPT in this setting require tailoring to each context [32].

206 In the absence of clear guidelines for TPT delivery in prisons, the PRISM/RE-AIM 207 framework provides an ideal heuristic for pre-implementation assessment to guide 208 future implementation. Though people in prison are the major target for TPT, their 209 access to treatment can be hindered or facilitated by multiple stakeholders, including 210 prison medical staff and custodial staff. We used this framework to prepare for a future 211 TPT implementation program in prisons, and, in collaboration with prison officer 212 stakeholders, explore potential implementation strategies based on themes prioritized 213 by prison personnel [33-37].

Though many of the barriers and facilitators to TPT may be common in prisons, it is important to tailor implementation to context. For example, in Malaysia, prison turnover has substantially increased with shortened stays in prison and multiple disruptions with transfers between housing units, prisons and to the community either for court appearances or medical appointments at government hospitals or release to home. Important here is that the prison officers were unaware of newer TPT options like 3 months of once-weekly isoniazid plus rifapentine (3HP). They perceived that switching

221 to this strategy rather than the standard 6 months of daily isoniazid preventive therapy 222 (IPT) would minimize disruptions in medication delivery due to typical and sometimes 223 unexpected logistical transfers. This short-course regimen with less frequent dosing has 224 higher acceptability and completion rates relative to IPT and may be especially useful in 225 prisons where high turnover logistical barriers undermine treatment completion 226 (14,17,20,22,37). Recent TPT programs in prisons in Thailand and Pakistan achieved 227 87-93% completion rates [20,21]. A prior systematic review of 6-month IPT completion 228 rates in prisons was substantially lower at 44%, reducing the enthusiasm for such a 229 strategy by international agencies [17]. Cited barriers by prison personnel was the 230 shortage of staff, insufficient knowledge and training, and a lack of prioritization for 231 prison health and resources by governmental authorities [38,39], which might partially 232 be solved by a once-weekly, 3HP short-course therapy that would reduce work 233 demands on staff and minimize security demands by minimizing movement by people in 234 prison. In addition, re-entry to the community and prison transfers are known high-risk 235 events for interruption in TB care.

236 Develop stakeholder inter-relationships

In the absence of a 3HP strategy, prison officers' top suggestion to optimize TPT was to enhance care coordination between prison officers and medical staff, which could be accomplished through local consensus discussions and checklists [10,23,40]. For example, prison officers could meet with medical personnel at the end of each week to discuss any anticipated transfer expected for the following week. In such cases, medical staff might try a number of approaches like prepare transfer medications to people who are moving to another prison or deliver medications the day before for offsite visits. As

there can be a tension between medical and custodial staff in terms of prioritizing health
vs security, creating a shared vision for creating a safe environment to minimize TB
transmission to personnel might align their missions. This is especially true in places
like Malaysia where in the absence of such a shared mission, prison personnel have
latent TB infection rates similar to people in prison due to a shared risk environment
[25].

250 Change infrastructure

251 The second-ranked implementation strategy supported by prison officers was to change 252 prison infrastructure to minimize disruptions due to transfers. Key among them, which 253 has been done in other prison settings, is to ensure that the TPT medications are closer 254 to housing units. instead of at the medical clinic, and provision of a temporary 255 medication supply accompanying the patient during transfers or release to finish their 256 treatment course. Though they did not provide specifics, this infrastructure change 257 might include the entire week's supply of medication being delivered to the housing unit 258 for dispensation, or in the case of daily observed therapy, having the medical staff make 259 daily deliveries to the housing unit rather than rely on a traditional "roll call" where 260 people in prison must leave their units to receive medications at the medical unit. An 261 alternative, but equally important suggestion was to have the custodial staff institute a 262 "medical hold" for any patients prescribed TPT, which would prevent such persons from 263 any kind of transfer until there was secondary clearance by a medical officer.

264 Training and Education

265 Though identified as a lower priority, prison officers also identified the need for more 266 trainings and knowledge about TB and TPT. Such a strategy could have benefits that 267 include creating a shared vision of reducing the risk for TB transmission to prison 268 personnel, but also to reduce TB incidence nationally in Malaysia. In many prisons, 269 including in Malaysia, only prison medical staff receive TB training from the Ministry of 270 Health. These trainings emphasize active TB and do not adequately address latent TB 271 or TPT. Unilateral training undermines any shared alignment for ensuring TPT. Formal 272 comprehensive training and knowledge-sharing on TB and TPT between medical and 273 non-medical prison staff could bridge the knowledge gap and emphasize the importance 274 of TPT and medication adherence to all personnel. In low-resource settings, educational 275 meetings and training workshops have strong evidence for improving patient outcomes. 276 For example, in Thai prisons, high health literacy among prison officers was associated 277 with good TB practices [42,43]. The U.S. Centers for Disease Control and Prevention 278 (CDC) also recommends all correctional officers in high risk facilities receive TB training 279 [43]. Further data are needed on knowledge level of TB and TPT and training needs for 280 prison staff but should be explored further.

Of interest here is the lack of discussion or prioritization of other key stakeholder relationships that might influence TPT delivery, like with the Ministry of Health and prison leadership. Political will is crucial for a successful response to TB in prisons [11,24,40]. This political will not only requires executive sponsorship from leadership, but also a financial commitment to prioritize TPT implementation in prisons [40]. In the case of prisons, it often requires a joint commitment by both the Ministry of Justice (or sometimes Interior) and Ministry of Health and unless both are fully

288 committed to prioritize TB control, then implementation efforts might not be fully 289 optimized. Stakeholder engagement and consensus-building will be important to bridge 290 conflicting priorities for criminal justice (security) and public health (prevention and 291 treatment) [11,40]. Such aligned engagement would be crucial to optimizing the national 292 budget for TB and ensure that a proportionate amount is allocated to TB control in 293 prisons. Given the limited amount of funding allocated to prisons and health, blended 294 implementation strategies that include a combination of low threshold strategies like 295 education and infrastructure changes as suggested by the officers may be low cost, 296 though care coordination and evaluative and iterative strategies may be needed to 297 change day-to-day operations. Such examples can include audit and feedback to 298 ensure that all people who enter prisons are screened for latent TB infection, and if 299 diagnosed, that there are methods to track TPT initiation and adherence to treatment. 300 This might involve creation of checklists to diagnose latent TB infection or dashboards 301 that track the number of people on treatment and notifying prison officers of adherence 302 rates with real-time feedback cycles.

303 Study Limitations

While there are many important and pragmatic perspectives listed and ranked by prison officers, this sample represents only one stakeholder group - the prison officers who control the movement of people in prison. As such, they represent one important gatekeeper to implementing TPT. Their perspective should be reviewed and triangulated with other stakeholders as was done recently when identifying and prioritizing barriers to implementing syringe services programs in prison in Canada

310 [29,44]. Future studies also need to involve other stakeholders, like clinicians in prison311 people in prison, and outer context authorities.

312 While a single NGT session might be insufficient to be fully representative or achieve

313 saturation, the findings here have face validity and accurately represent known barriers.

314 Their solutions, however, might represent an initial plan to select and prioritize

315 implementation strategies and follow-up NGT could be done to determine if the

316 observed barriers were successfully overcome.

317 Lastly, while the barriers and facilitators represent the perception by the officers, they 318 may not be fully accurate. For example, in this session, a substantial number of officers 319 changed their vote after learning about an innovative TPT strategy – a 3-month TPT 320 regimen that requires administration only once per week. Thus, in the absence of being 321 informed by ideas outside the prison, their selection of implementation strategies may 322 not fully align with all the true possibilities. Notwithstanding these limitations, the ideas 323 generated provide a heuristic for implementing actionable changes to optimize TPT 324 delivery in Malaysian prisons.

325 Conclusions

326 Despite several decades of TPT and strong evidence supporting its efficacy,

327 implementation of TPT in prisons has been limited with challenges in adherence and

328 completion rates. However, prisons are sentinel sites for TB reactivation, transmission,

329 and development of MDR TB with dire public health consequences. Prioritizing more

330 stakeholder engagement, changes to infrastructure and logistical processes, and

331 resources to optimize TPT implementation in prisons may greatly improve TB control. In

- the future, this pre-implementation framework may be a useful model for other prisons
- in Malaysia and other low-resource settings.

334 Acknowledgements

- 335 We appreciate support for this project from the Malaysian Ministry of Health, Prisons
- 336 Department, and Centre of Excellence for Research in AIDS, University Malaya.

337 References

- 1. The top 10 causes of death. WHO. 2024 [cited 29 Aug 2024]. Available:
- 339 https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

340 2. Implementing the end TB strategy: the essentials, 2022 update. WHO; 2022 Dec.
341 Available: https://www.who.int/publications/i/item/9789240065093

- 342 3. Global tuberculosis report 2023. Geneva; 2023. Available:
- 343 https://www.who.int/publications/i/item/9789240083851
- Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al.
 Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.
 Lancet. 2016;388: 1089–1102. doi:10.1016/S0140-6736(16)30466-4
- 5. Ding C, Hu M, Guo W, Hu W, Li X, Wang S, et al. Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990–2019.
- 349 International Journal of Infectious Diseases. 2022;122: 46–62.
- 350 doi:10.1016/j.ijid.2022.05.029
- Al-Darraji HAA, Kamarulzaman A, Altice FL. Latent tuberculosis infection in a
 Malaysian prison: implications for a comprehensive integrated control program in
 prisons. BMC Public Health. 2014;14: 22. doi:10.1186/1471-2458-14-22
- 7. Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. High
 Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. Open Forum
 Infectious Diseases. 2023;10. doi:10.1093/ofid/ofad500.1729
- Margolis B, Al-Darraji HAA, Wickersham JA, Kamarulzaman A, Altice FL.
 Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners
 in northeastern Malaysia. The International Journal of Tuberculosis and Lung Disease.
 2013;17: 1538–1544. doi:10.5588/ijtld.13.0193

361 9. Ahmad A, Kamarulzaman A, Kazatchkine M, Dreifuss R, Clark H. The 67th UN
362 CND—upholding human rights in drug policy. The Lancet. 2024;403: 1851–1852.
363 doi:10.1016/S0140-6736(24)00763-3

10. Charalambous S, Velen K, Rueda Z, Croda J, Herce ME, Shenoi SV, et al.
Scaling up evidence-based approaches to tuberculosis screening in prisons. The Lancet
Public Health. 2023;8: e305–e310. doi:10.1016/S2468-2667(23)00002-6

11. Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et
al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and
tuberculosis in prisoners. Lancet. 2016;388: 1115–1126. doi:10.1016/S01406736(16)30769-3

12. Laws of Malaysia. (2000). Peraturan-peraturan Penjara 2000. The Commissionerof Law Revision, Malaysia.

373 13. Baharudin MN, Mohamad M, Karim F. Drug-abuse inmates maqasid shariah
374 quality of life: a conceptual paper. Humanities & Social Sciences Reviews. [cited 17 Jul
375 2024]. doi:https://doi.org/10.18510/hssr.2020.83131

Narayan A, Salindri AD, Keshavjee S, Muyoyeta M, Velen K, Rueda ZV, et al.
Prioritizing persons deprived of liberty in global guidelines for tuberculosis preventive
treatment. PLoS Med. 2023;20: e1004288. doi:10.1371/journal.pmed.1004288

Tuberculosis preventive treatment: rapid communication. [cited 26 Jun 2024].
Available: https://www.who.int/publications/i/item/9789240089723

381 16. Bhargava A. The 3 HP regimen for tuberculosis preventive treatment: safety,

382 dosage and related concerns during its large-scale implementation in countries like

383India. The Lancet Regional Health - Southeast Asia. 2024;0.

384 doi:10.1016/j.lansea.2024.100422

Al-Darraji HAA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in
correctional facilities: a systematic review. The International Journal of Tuberculosis and
Lung Disease. 2012;16: 871–879. doi:10.5588/ijtld.11.0447

18. Warren JL, Grandjean L, Moore DAJ, Lithgow A, Coronel J, Sheen P, et al.
Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and
molecular epidemiological analysis. BMC Med. 2018;16: 122. doi:10.1186/s12916-0181111-x

392 19. Gygli SM, Loiseau C, Jugheli L, Adamia N, Trauner A, Reinhard M, et al. Prisons
393 as ecological drivers of fitness-compensated multidrug-resistant Mycobacterium
394 tuberculosis. Nat Med. 2021;27: 1171–1177. doi:10.1038/s41591-021-01358-x

Mapingure MP, Zech JM, Hirsch-Moverman Y, Msukwa M, Howard AA, Makoni
T, et al. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast
Track HIV treatment model: experiences from a pilot study. Journal of the International
AIDS Society. 2023;26: e26105. doi:10.1002/jia2.26105

399 21. Gatechompol S, Harnpariphan W, Supanan R, Suwanpimolkul G, Sophonphan J,
400 Ubolyam S, et al. Prevalence of latent tuberculosis infection and feasibility of TB
401 preventive therapy among Thai prisoners: a cross-sectional study. BMC Public Health.
402 2021;21: 1206. doi:10.1186/s12889-021-11271-0

403 22. Chimoyi L, Smith H, Hausler H, Fielding K, Hoffmann CJ, Herce ME, et al.
404 Delivery of TB preventive therapy to incarcerated people living with HIV in southern
405 African correctional facilities. Public Health Action. 2021;11: 171–173.
406 doi:10.5588/pha.21.0056

407 23. Aguiar A, Abreu M, Duarte R. Healthcare professionals perspectives on
408 tuberculosis barriers in Portuguese prisons—a qualitative study. Journal of Public
409 Health. 2024; fdae065. doi:10.1093/pubmed/fdae065

410 24. Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural
411 barriers to implementing recommended tuberculosis preventive treatment in primary
412 care clinics in rural South Africa. Glob Public Health. 2022;17: 555–568.
413 doi:10.1080/17441692.2021.1892793

Al-Darraji HAA, Tan C, Kamarulzaman A, Altice FL. Prevalence and correlates of
latent tuberculosis infection among employees of a high security prison in Malaysia.
Occup Environ Med. 2015;72: 442–447. doi:10.1136/oemed-2014-102695

417 26. Security & Intelligence Division, Malaysian Prison Department (2024). Lokaliti418 Penjara Semasa.

419 27. Guidelines for Tuberculosis Control in Prison Institutions in Malaysia. Ministry of420 Health, Malaysia; 2017.

421 28. Madden L, Bojko MJ, Farnum S, Mazhnaya A, Fomenko T, Marcus R, et al.
422 Using nominal group technique among clinical providers to identify barriers and
423 prioritize solutions to scaling up opioid agonist therapies in Ukraine. Int J Drug Policy.
424 2017;40: 48, 52, doi:10.1016/j.drugpo.2017.07.025

424 2017;49: 48–53. doi:10.1016/j.drugpo.2017.07.025

425 29. DiDomizio E, Chandra DK, Nichols L, Villanueva M, Altice FL. Challenges to
426 Achieving HCV Micro-Elimination in People With HIV in the United States: Provider
427 Perspectives and the Role of Implicit Bias. Health Promot Pract. 2023;24: 998–1008.
428 doi:10.1177/15248399231169928

30. Kronfli N, Lafferty L, Leone F, Stoové M, Hajarizadeh B, Lloyd AR, et al. Using
nominal group technique to identify perceived barriers and facilitators to improving
uptake of the Prison Needle Exchange Program in Canadian federal prisons by
correctional officers and healthcare workers. Int J Drug Policy. 2024;130: 104540.
doi:10.1016/j.drugpo.2024.104540

434 31. Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using
435 nominal group technique to identify barriers, facilitators, and preferences among
436 patients seeking treatment for opioid use disorder: A needs assessment for decision
437 making support. J Subst Abuse Treat. 2019;100: 18–28. doi:10.1016/j.jsat.2019.01.019

32. Rosen AO, Wickersham JA, Altice FL, Khati A, Azwa I, Tee V, et al. Barriers and
Facilitators to Pre-Exposure Prophylaxis by Men Who Have Sex with Men and
Community Stakeholders in Malaysia. Int J Environ Res Public Health. 2023;20: 5669.
doi:10.3390/ijerph20095669

442 33. Isoniazid vs. 3HP: treatment completion and adverse events in a RCT conducted
443 in the largest prison in Malaysia. The Union World Conference on Lung Health 2024;
444 2024 Nov; Bali.

Waltz TJ, Powell BJ, Matthieu MM, Damschroder LJ, Chinman MJ, Smith JL, et
al. Use of concept mapping to characterize relationships among implementation
strategies and assess their feasibility and importance: results from the Expert
Recommendations for Implementing Change (ERIC) study. Implementation Science.
2015;10: 109. doi:10.1186/s13012-015-0295-0

450 35. Kirchner, J. E., Waltz, T. J., Powell, B. J., Smith, J. L., & Proctor, E. K. RC.
451 Implementation strategies. Dissemination and Implementation Research in Health. 2nd
452 ed. 2018.

453 36. Lovero KL, Kemp CG, Wagenaar BH, Giusto A, Greene MC, Powell BJ, et al. 454 Application of the Expert Recommendations for Implementing Change (ERIC)

455 compilation of strategies to health intervention implementation in low- and middle-

456 income countries: a systematic review. Implementation Science. 2023;18: 56.

457 doi:10.1186/s13012-023-01310-2

458 37. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et
459 al. A refined compilation of implementation strategies: results from the Expert
460 Recommendations for Implementing Change (ERIC) project. Implementation Science.

461 2015;10: 21. doi:10.1186/s13012-015-0209-1

38. Yakovchenko V, Chinman MJ, Lamorte C, Powell BJ, Waltz TJ, Merante M, et al.
Refining Expert Recommendations for Implementing Change (ERIC) strategy surveys

using cognitive interviews with frontline providers. Implementation Science
Communications. 2023;4: 42. doi:10.1186/s43058-023-00409-3

466 39. Hinduan ZR, Suherman H, Pinxten WJL, Alisjahbana B, Hospers HJ. HIV-related
467 knowledge and attitudes among Indonesian prison officers. Int J Prison Health. 2013;9:
468 92–102. doi:10.1108/17449201311326961

469 40. Rosen DL, Blue C, Brown M, Bradley-Bull S, DiRosa EA, Carda-Auten J. The
470 role of detention officers in the provision of jail healthcare in the Southeastern United
471 States. Soc Sci Med. 2023;330: 116065. doi:10.1016/j.socscimed.2023.116065

472 41. Dara M, Acosta CD, Melchers NVSV, Al-Darraji HAA, Chorgoliani D, Reyes H, et
473 al. Tuberculosis control in prisons: current situation and research gaps. Int J Infect Dis.
474 2015;32: 111–117. doi:10.1016/j.ijid.2014.12.029

475 42. Pantoja T, Opiyo N, Lewin S, Paulsen E, Ciapponi A, Wiysonge CS, et al.

476 Implementation strategies for health systems in low-income countries: an overview of

477 systematic reviews. Cochrane Database Syst Rev. 2017;2017: CD011086.

478 doi:10.1002/14651858.CD011086.pub2

479 43. Rakpaitoon S, Thanapop S, Thanapop C. Correctional Officers' Health Literacy
480 and Practices for Pulmonary Tuberculosis Prevention in Prison. Int J Environ Res Public
481 Health. 2022;19: 11297. doi:10.3390/ijerph191811297

482 44. Prevention and Control of Tuberculosis in Correctional and Detention Facilities:

483 Recommendations from CDC: Endorsed by the Advisory Council for the Elimination of

484 Tuberculosis, the National Commission on Correctional Health Care, and the American

485 Correctional Association. [cited 26 Jun 2024]. Available:

486 https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5509a1.htm

487 45. Lafferty L, Altice FL, Leone F, Stoové M, Lloyd AR, Hajarizadeh B, et al. Using
488 nominal group technique with people who are incarcerated in Canadian federal prisons
489 to identify barriers and solutions to improving Prison Needle Exchange Program uptake.

490 International Journal of Drug Policy. 2024;131: 104549.

491 doi:10.1016/j.drugpo.2024.104549